---
title: "Tianjin Pharmaceutical Da Ren Tang unit wins China approval for saxagliptin-metformin sustained-release tablets"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295236347.md"
description: "Tianjin Pharmaceutical Da Ren Tang Group secured NMPA approval for saxagliptin-metformin sustained-release tablets via its Xinxin plant. The Category 4 filing passed China's quality and efficacy consistency evaluation. Production will be handled by Jiangsu Yongan Pharmaceutical, with the approval not expected to materially impact near-term financial performance. China sales of the drug reached approximately RMB 480 million in 2025, a 33% increase from 2024."
datetime: "2026-08-07T12:41:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295236347.md)
  - [en](https://longbridge.com/en/news/295236347.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295236347.md)
generator: "portal-rs"
---

# Tianjin Pharmaceutical Da Ren Tang unit wins China approval for saxagliptin-metformin sustained-release tablets

-   Tianjin Pharmaceutical Da Ren Tang Group secured NMPA registration for saxagliptin-metformin sustained-release tablets (I) via its Xinxin plant. \* The chemical-drug Category 4 filing is deemed to have passed China’s quality and efficacy consistency evaluation. \* The approval is not expected to materially affect near-term financial performance; production will be manufactured by Jiangsu Yongan Pharmaceutical. \* China sales of the drug totaled about RMB 480 million in 2025, up about 33% from 2024. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tianjin Pharmaceutical Da Ren Tang Group Corporation Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: P0AH3R2IYB3JIPG3) on August 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [600329.CN](https://longbridge.com/en/quote/600329.CN.md)
- [T14.SG](https://longbridge.com/en/quote/T14.SG.md)
- [S68.SG](https://longbridge.com/en/quote/S68.SG.md)

## Related News & Research

- [Tianjin Pharmaceutical Da Ren Tang enters annual distribution deal with Taiping Medicine, Zhongxin Medicine](https://longbridge.com/en/news/295236477.md)
- [Hunan High-Tech Industry Investment chair Li Aidong visits Tianjin Pharma for operations review](https://longbridge.com/en/news/295429562.md)
- [CANSINOBIO  Tetanus Vaccine New Drug Application Approved](https://longbridge.com/en/news/296498620.md)
- [HENGRUI PHARMA  1H26 Net Profit Rises 0.3% YoY to RMB4.465 Billion; Shares Now Down Over 7%](https://longbridge.com/en/news/296422700.md)
- [Cribl acquires Radiant Security AI SOC technology assets](https://longbridge.com/en/news/296374753.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**